Back

Elamipretide improves mitochondrial activity in the failing human heart.

22 May 2016 (13:00 - 13:15)
Organised by:
Congress Presentation Part of: Targeting mitochondria to improve outcomes in heart failure Cell Signalling HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Doctor Brian Stauffer

University of Colorado Anschutz Medical Campus, Aurora (United States of America)

3 More presentations in this session

Presentation thumbnail
Reaching the next level of drug development for heart failure: targetting mitochondria.
Professor S. Anker (Berlin, DE)
Presentation thumbnail
Elamipretide in heart failure with reduced ejection fraction.
Professor H. Sabbah (Detroit, US)
Presentation thumbnail
Clinical development concepts targeting mitochondria.
Professor B. Pitt (Ann Arbor, US)

Access the full session

Session thumbnail
Targeting mitochondria to improve outcomes in heart failure

The Event

Event poster

HEART FAILURE 2016

22 May 2016 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Mitochondrial targeting by Elamipretide improves cardiac mitochondrial function without improving cardiovascular performance in HFpEF
23 April 2026
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Effect of SGLT2i empagliflozin on left ventricular and mitochondrial function in a porcine model of anthracycline-induced cardiotoxicity
20 May 2023
thumbnail
Congress Session
New frontiers in heart failure therapies
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources